It has been shown after a follow-up of more than 3 years that first-line pembrolizumab monotherapy provides durable long-term overall survival (OS) compared to chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). This OS benefit was observed despite 65% of patients assigned to chemotherapy crossing over to pembrolizumab. Furthermore, pembrolizumab had a manageable long-term safety profile.
Dr Martin Reck (Lung Clinic Grosshansdorf, Germany) presented data on 3-year survival from the KEYNOTE-024. Patients with advanced NSCLC who had programmed death-ligand 1 (PD-L1) ≥50% and who had no targetable epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) alterations had been randomised to pembrolizumab or platinum-based chemotherapy. Earlier results had already shown that first-line pembrolizumab significantly improved progression-free survival (PFS) as well as OS compared with chemotherapy .
For this longer fol...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Older Age and Low Neutrophilia Inflammation Predictor for Osimertinib Efficacy Next Article
Challenges in diagnosing and treating progressive MS »
Table of Contents: WCLC 2019
Screening, Detection, and Diagnosis
Non-Small-Cell Lung Cancer
Other Thoracic Malignancies
Phase 3 Trial Updates
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.